Office of Commercialization and Economic Development
Office of Technology Commercialization

Highly Specific and Neutralizing Therapeutic Antibodies for Zika Virus

Technology #18-0023

Our investigators have identified two highly specific and neutralizing antibodies isolated from a traveler naïve to all serotypes of Dengue. The antibodies (A9E and G9E) can be used against 7 different Zika virus types and react only to Zika virus and no other flaviviruses.

•Diagnosis and treatment of Zika virus infection.
•Antibody sequences for vaccine development.

•Non-reactive to Dangue and other flavivviruses.
•Fully characterized binding site.
•More potent and highly specific than currently available Ziki antibodies.

Related Publications: